921 filings
6-K
ONCY
Oncolytics Biotech, Inc.
12 Apr 24
Notice of Annual General Meeting
11:03am
6-K
ONCY
Oncolytics Biotech, Inc.
11 Apr 24
Oncolytics Biotech® Advances Toward Registration-Enabling Trial for Pelareorep in Breast Cancer with Submission of Type C Meeting Request to FDA
10:03am
6-K
ONCY
Oncolytics Biotech, Inc.
2 Apr 24
Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity’s Horizons in Oncology Virtual Conference
8:02am
6-K
ONCY
Oncolytics Biotech, Inc.
7 Mar 24
Oncolytics Biotech® Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights
4:06pm
6-K
ONCY
Oncolytics Biotech, Inc.
5 Mar 24
Oncolytics Biotech® Files Amendment to Initiate New Pancreatic Cancer GOBLET Cohort Supported by PanCAN
1:08pm
6-K
wkiqw67s05kns74pc1
4 Mar 24
Oncolytics Biotech® to Host Conference Call to Discuss Fourth Quarter and Full Year Financial Results and Recent Operational Highlights
12:37pm
6-K
e4l6vao47o73vsq
28 Feb 24
Oncolytics Biotech® Announces Presentation at the Cancer Advocacy Group of Louisiana’s 3rd Annual NeauxCancer Conference
1:09pm
6-K
rtf gthewfxjsc
14 Feb 24
Current report (foreign)
8:30am
6-K
ft9axh ue0p1hlu
9 Jan 24
Oncolytics Biotech® Appoints Patricia S. Andrews to its Board of Directors
8:44am
6-K
4ckme8n342n6tvjm 2s
4 Jan 24
Oncolytics Biotech® Recaps 2023 Accomplishments, Provides Outlook for 2024
1:01pm
6-K
cpql7fq
7 Dec 23
Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS
10:37am
6-K
s1pdflerfdsx
9 Nov 23
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy
1:21pm
6-K
cqkuq1qh75m36
9 Nov 23
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep
1:00pm
6-K
yjpj9gjus4nom2p6ze
3 Nov 23
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC
2:01pm
6-K
yvp42
3 Nov 23
Condensed Interim Consolidated Financial Statements
11:18am
6-K
egen3dnp66yofe
3 Nov 23
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights
11:17am
6-K
qvn366u3nlzk fh
23 Oct 23
Oncolytics Presents Positive Updated Pancreatic Cancer Data from GOBLET Phase 1/2 Study at ESMO
12:33pm
6-K
kbnke1
23 Oct 23
Oncolytics Achieves Success Criteria for Efficacy in the Third-Line Colorectal Cancer Cohort of the GOBLET Study
12:26pm
6-K
vu04z0o0br18i5z ib7x
20 Oct 23
Oncolytics Biotech® to Host Conference Call to Discuss Third Quarter Financial Results and Recent Operational Highlights
3:07pm
6-K
suw9v3 5cbis
16 Oct 23
Oncolytics Biotech® To Present Two Posters on the Pelareorep-Based GOBLET Study at ESMO 2023
1:20pm